OR WAIT null SECS
Parties expect improved design and selection of eCOAs in decentralized clinical trials
Thread, a technology and service provider that enables decentralized clinical trials (DCTs), has acquired Modus Outcomes in order to merge high-technology and high-science into one platform. Financial details of the acquisition are not being disclosed, but with Modus being a research consultancy that supports the design and selection of electronic clinical outcome assessments (eCOAs), participant-focused trial design and scientific delivery of DCTs, the goal of the platform is to achieve higher-quality outcomes for research sponsors.
As clinical trials have become more intricate, designing and implementing endpoints has also become more involved. With this deal, Thread will bring together its eCOA technology platform with Modus’ services in order to offer biopharma and contract research organizations a product that improves their decision-making for developing and commercializing new therapies.
“The shared values, approach and need for humanistic input to DCTs make this milestone acquisition a win for the industry,” says Patrick Marquis, MD, Modus Outcomes CEO. “We are thrilled to join the Thread team and work closely with customers and partners to achieve patient-centric outcomes.”